Mga Batayang Estadistika
| CIK | 1781174 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Acrivon Therapeutics, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| September 5, 2025 |
FORM 8-K Item 7.01 Regulation FD Disclosure. Item 9.01 Financial Statements and Exhibits. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 05, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 5, 2025 |
ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) NEXT GENERATION PRECISION MEDICINE CORPORATE PRESENTATION SEPTEMBER 2025 Exhibit 99. |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Th |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2025 |
Exhibit 99.1 Acrivon Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights Continued advancement of two clinical-stage assets, both with clinically demonstrated single-agent anti-tumor activity - ACR-368 in a registrational-intent Phase 2 study in endometrial cancer and ACR-2316 in a Phase 1 study in AP3-predicted tumor types New paradigm for accelerated design and dev |
|
| June 13, 2025 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2025 |
Acrivon Therapeutics, Inc. Amended and Restated 2023 Inducement Plan. Exhibit 4.3 ACRIVON THERAPEUTICS, INC. AMENDED AND RESTATED 2023 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Acrivon Therapeutics, Inc. Amended and Restated 2023 Inducement Plan (this “Plan”) of Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the C |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon T |
|
| May 14, 2025 |
As filed with the Securities and Exchange Commission on May 14, 2025 As filed with the Securities and Exchange Commission on May 14, 2025 Registration No. |
|
| May 14, 2025 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Table FORM S-8 (Form Type) ACRIVON THERAPEUTICS, INC. |
|
| May 14, 2025 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2025 |
Exhibit 99.1 Acrivon Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Corporate R&D event highlighted positive ACR-368 data in endometrial cancer patients who had all received prior anti-PD-1 and platinum-based chemotherapy Confirmed overall response rate (cORR) of 35% and median duration of response (mDOR) >5.6 months (not yet reached) observed in OncoSignature-po |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| April 7, 2025 |
Exhibit 99.1 Acrivon Therapeutics Appoints World-Renowned Oncology Key Opinion Leader and Clinical Investigator Mansoor Raza Mirza, M.D., as Chief Medical Officer Distinguished, highly accomplished clinician with stellar track record of successfully leading numerous registrational trials through global regulatory approvals, and establishing new standards of care in gynecological oncology over the |
|
| April 7, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 07, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 28, 2025 |
Calculation of Filing Fee Table. Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 Acrivon Therapeutics, Inc. |
|
| March 28, 2025 |
As filed with the Securities and Exchange Commission on March 28, 2025 As filed with the Securities and Exchange Commission on March 28, 2025 Registration No. |
|
| March 27, 2025 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 27, 2025 |
Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acrivon Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, $0.001 par value per share (the “common stock”). For the purpose of this exhibit, unless the context o |
|
| March 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41551 Acrivon Therape |
|
| March 27, 2025 |
Exhibit 99.1 Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results Generative Phosphoproteomics AP3 platform designed to enable streamlined, rational drug discovery, with proprietary, proteome-wide SAR delivering desirable pathway effects R&D event highlighted positive ACR-368 endometrial cancer data in OncoSignature-positive (BM+) patients with heav |
|
| March 27, 2025 |
Exhibit 21.1 ACRIVON THERAPEUTICS, INC. SUBSIDIARIES 1. Acrivon AB, a joint stock company incorporated under the laws of Sweden 2. Acrivon Securities Corporation, a Massachusetts corporation |
|
| March 27, 2025 |
Exhibit 19.1 Acrivon therapeutics, inc. Insider trading policy (Revised June 2024) Introduction During the course of your relationship with Acrivon Therapeutics, Inc. (the “Company”), you may receive material information that is not yet publicly available (“inside information” or “material nonpublic information”) about the Company or other publicly traded companies with which the Company has busin |
|
| March 25, 2025 |
CORPORATE R&D EVENT March 25, 2025 CORPORATE R&D EVENT March 25, 2025 Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations. |
|
| March 25, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 25, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 14, 2025 |
Amended Offer Letter, between the Company and Adam Levy, dated March 14, 2025. Exhibit 10.1 March 14, 2025 Adam Levy, PhD, MBA 9754 Crystal Ridge Drive Escondido, CA 92026 RE: Amendment No. 2 to Offer Letter Dear Adam: As you know, you are currently performing services for Acrivon Therapeutics Inc. (the “Company”) pursuant to the terms of an offer letter effective June 23, 2023, as amended by the offer letter amendment, dated March 11, 2024 (together, the “Offer Letter”). Th |
|
| March 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2025 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| November 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 13, 2024 |
Exhibit 99.1 Acrivon Therapeutics Reports Third Quarter 2024 Financial Results and Business Highlights - Positive clinical data with confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) and prospective ACR-368 OncoSignature patient selection (p = 0.009) from ongoing ACR-368 registrational-intent Phase 2b endometrial cancer study presented at ESMO - Endometrial cancer, a tumor type ide |
|
| November 13, 2024 |
Exhibit 10.1 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT This FOURTH AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (this “Fourth Amendment”) is effective as of September 30, |
|
| November 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| October 11, 2024 |
Exhibit 99.1 Acrivon Therapeutics Announces Initial Patient Dosing in Phase 1 Trial of ACR-2316, a Novel WEE1/PKMYT1 Inhibitor Designed Using AP3 for Superior Single-Agent Activity - First patient dosed two quarters ahead of original timelines in Acrivon Phase 1 study to assess safety and tolerability of ACR-2316 - ACR-2316 was internally discovered and advanced in 15 months from initial lead to P |
|
| October 11, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 11, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commis |
|
| September 16, 2024 |
EX-99.1 Exhibit 99.1 Acrivon Therapeutics Reports Positive Endometrial Cancer Data from Ongoing ACR-368 Registrational Intent Phase 2 Study at ESMO, Advancement of ACR-2316 into Clinic Ahead of Timelines, and Progress on its AP3 Interactome for Proprietary Data Analysis - Confirmed overall response rate (ORR) = 62.5% (95% CI, 30.4-86.5) observed in prospectively-selected ACR-368 OncoSignature-pos |
|
| September 16, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 14, 2024 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Comm |
|
| September 16, 2024 |
EX-99.2 CORPORATE R&D EVENT September 14, 2024 ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE Exhibit 99.2 Forward-looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or |
|
| August 13, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 13, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| August 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| August 13, 2024 |
Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights Acrivon Therapeutics Reports Second Quarter 2024 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 13, 2024 – Acrivon Therapeutics, Inc. |
|
| July 10, 2024 |
ACRV / Acrivon Therapeutics, Inc. / Chione Ltd - AMENDMENT NO. 2 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0208963-13ga2chioneacri.htm AMENDMENT NO. 2 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 004890109 (CUSIP Number) June 30, 2024 (Date of Event Which Requires Filing of this Stateme |
|
| July 10, 2024 |
EX-24.1 2 ea020896301ex24-1acrivon.htm POWER OF ATTORNEY, DATED MAY 15, 2024, MADE BY MARCIN CZERNIK AND CHIONE LIMITED IN FAVOR OF SHALOM LEAF Exhibit 24.1 LIMITED POWER OF ATTORNEY The undersigned, Marcin Czernik, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if appl |
|
| July 10, 2024 |
ACRV / Acrivon Therapeutics, Inc. / Chione Ltd - AMENDMENT NO. 1 TO SCHEDULE 13G Passive Investment SC 13G/A 1 ea0208963-13ga1chioneacri.htm AMENDMENT NO. 1 TO SCHEDULE 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 004890109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Sta |
|
| July 10, 2024 |
Joint Filing Agreement, dated July 10, 2024, among the Reporting Persons EX-99.1 6 ea020896301ex99-1acrivon.htm JOINT FILING AGREEMENT, DATED JULY 10, 2024, AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by |
|
| July 10, 2024 |
Power of Attorney, dated May 15, 2024, made by Wiaczeslaw Smolokowski in favor of Shalom Leaf EX-24.3 4 ea020896301ex24-3acrivon.htm POWER OF ATTORNEY, DATED MAY 15, 2024, MADE BY WIACZESLAW SMOLOKOWSKI IN FAVOR OF SHALOM LEAF Exhibit 24.3 LIMITED POWER OF ATTORNEY The undersigned, Wiaczeslaw Smolokowski, hereby appoints Shalom Leaf as his attorney-in-fact for and on behalf of the undersigned, in respect of (A) any current or future direct or indirect beneficial ownership of, or pecuniary |
|
| July 10, 2024 |
EX-24.2 3 ea020896301ex24-2acrivon.htm POWER OF ATTORNEY, DATED MAY 15, 2024, MADE BY ANDREAS HADJIMICHAEL AND CHIONE LIMITED IN FAVOR OF SHALOM LEAF Exhibit 24.2 LIMITED POWER OF ATTORNEY The undersigned, Andreas Hadjimichael, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director |
|
| July 10, 2024 |
Joint Filing Agreement, dated July 10, 2024, among the Reporting Persons EX-99.1 2 ea020896302ex99-1acrivon.htm JOINT FILING AGREEMENT, DATED JULY 10, 2024, AMONG THE REPORTING PERSONS Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the “Exchange Act”), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by |
|
| July 10, 2024 |
Exhibit 24.4 LIMITED POWER OF ATTORNEY The undersigned, Anastasis Nikolaou, hereby appoints Shalom Leaf as his attorney-in-fact (i) for and on behalf of the undersigned, including, without limitation, in my current or future capacity as a director and, if applicable, as an officer of Chione Limited (the “Company”), and (ii) for and on behalf of the Company, in each case, in respect of (A) any curr |
|
| June 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 20, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 14, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| May 14, 2024 |
Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights Acrivon Therapeutics Reports First Quarter 2024 Financial Results and Business Highlights WATERTOWN, Massachusetts, May 14, 2024 – Acrivon Therapeutics, Inc. |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Definit |
|
| April 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| April 24, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 24, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 24, 2024 |
Exhibit 99.2 Acrivon Therapeutics Reports Initial Positive Clinical Data for ACR-368 and Pipeline Program Progress Today at Corporate R&D Event • Initial ACR-368 Phase 2b clinical data in patients with ovarian or endometrial cancers (n=26; 10 OncoSignature-positive and 16 OncoSignature-negative) are being presented • A 50% confirmed overall response rate observed with ACR-368 in OncoSignature-posi |
|
| April 24, 2024 |
CORPORATE R&D EVENT APRIL 24, 2024 ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE Forward-looking statements -looking statements Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regarding our future results of operations or financial condition, business strategy and plans and objectives of management for future operations. |
|
| April 24, 2024 |
April 24, 2024 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Chris Edwards Re: Acrivon Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-278761 Acceleration Request Requested Date: April 29, 2024 Requested Time: 9:00 A.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 under th |
|
| April 17, 2024 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acrivon Therapeutics, Inc. |
|
| April 17, 2024 |
As filed with the Securities and Exchange Commission on April 17, 2024. S-3 Table of Contents As filed with the Securities and Exchange Commission on April 17, 2024. |
|
| April 15, 2024 |
EX-99.1 2 d814552dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: April 15, 2024 |
|
| April 15, 2024 |
ACRV / Acrivon Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 3)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) April 11, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to de |
|
| April 11, 2024 |
ACRV / Acrivon Therapeutics, Inc. / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment SC 13D/A 1 tm2411635d1sc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Acrivon Therapeutics, Inc. (Name of Issuer) Common stock, $0.001 par value per share (Title of Class of Securities) 004890109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, M |
|
| April 9, 2024 |
Acrivon Therapeutics Announces $130 Million Private Placement Financing Exhibit 99.1 Acrivon Therapeutics Announces $130 Million Private Placement Financing WATERTOWN, Massachusetts, April 9, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing |
|
| April 9, 2024 |
Exhibit 4.1 FORM OF PRE-FUNDED WARRANT TO PURCHASE COMMON STOCK Number of Shares: [ ] (subject to adjustment) Warrant No. Original Issue Date: April [ ], 2024 Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [ ] or its registered assigns (the “Holder”), is en |
|
| April 9, 2024 |
Form of Registration Rights Agreement Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”), dated as of April 8, 2024, is entered into by and among ACRIVON THERAPEUTICS, INC., a Delaware corporation (the “Company”), and the several investors signatory hereto (individually as an “Investor” and collectively together with their respective permitted assigns, the “Investors”). Capitalized terms u |
|
| April 9, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT BY AND AMONG ACRIVON THERAPEUTICS, INC., AND THE PURCHASERS AS SET FORTH HEREIN April 8, 2024 TABLE OF CONTENTS 1. Definitions 1 2. Purchase and Sale of Securities 5 2.1 Purchase and Sale 5 2.2 Closing 6 3. Representations and Warranties of the Company 6 3.1 Organization and Power 6 3.2 Capitalization 7 3.3 Registration Rights 7 3.4 Authorization 7 3.5 Va |
|
| April 9, 2024 |
Exhibit 10.4 [COMPANY LETTERHEAD] April [], 2024 [] Re: Affiliate Registration Rights Agreement Ladies and Gentlemen: Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [] (collectively, the “Investor”), the parties to this letter hereby agree as follows: 1. Affiliate Registration Rights Agreement. The Company agrees, upon a w |
|
| April 9, 2024 |
Exhibit 10.3 [COMPANY LETTERHEAD] April [], 2024 [] Re: Publicity and Board Observer Rights Ladies and Gentlemen: Subject to and in consideration of an investment in Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), by [] and/or one or more of its Affiliates (as defined below) (each, an “Investor” and together, the “Investors”), the parties to this letter hereby agree as follows: |
|
| April 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 08, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 29, 2024 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 Acrivon Therapeutics, Inc. |
|
| March 29, 2024 |
As filed with the Securities and Exchange Commission on March 29, 2024 As filed with the Securities and Exchange Commission on March 29, 2024 Registration No. |
|
| March 28, 2024 |
Exhibit 21.1 ACRIVON THERAPEUTICS, INC. SUBSIDIARIES 1. Acrivon AB, a joint stock company incorporated under the laws of Sweden 2. Acrivon Securities Corporation, a Massachusetts corporation |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41551 Acrivon Therape |
|
| March 28, 2024 |
Exhibit 10.16 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. THIRD AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT This Third Amendment to Oncosignature Companion Diagnostic Agreement (the “Third Amendment”) is made and entered into as of Dece |
|
| March 28, 2024 |
Policy on Recoupment of Incentive Compensation. ACRIVON THERAPEUTICS, INC. POLICY ON RECOUPMENT OF INCENTIVE COMPENSATION Introduction The Compensation Committee (the “Compensation Committee”) of the Board of Directors (the “Board”) of Acrivon Therapeutics, Inc. (the “Company”) has adopted this Policy on Recoupment of Incentive Compensation (this “Policy”), which provides for the recoupment of compensation in certain circumstances in the event |
|
| March 28, 2024 |
Exhibit 10.15 CERTAIN CONFIDENTIAL INFORMATION, MARKED BY [***], HAS BEEN EXCLUDED FROM THIS EXHIBIT BECAUSE IT (I) IS NOT MATERIAL AND (II) IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT This SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (the “Second Amendment”) is made and entered into as of J |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Acrivon Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 28, 2024 |
Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, March 28, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to e |
|
| March 28, 2024 |
Description of registrant’s securities. Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acrivon Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, $0.001 par value per share (the “common stock”). For the purpose of this exhibit, unless the context o |
|
| March 28, 2024 |
Exhibit 10.13 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”), is entered into this 30th day of May, 2023, and is by and between Acrivon Therapeutics Inc., a Delaware corporation (“Company”), and Kristina M. Masson (“Executive”), and made effective as of June 1, 2023 (the “A&R Effective Date”). WHEREAS, the Company and |
|
| March 4, 2024 |
Exhibit 99.1 Acrivon Therapeutics Appoints Santhosh Palani, Ph.D., CFA, Experienced Board Member and Healthcare Investor, to its Board of Directors WATERTOWN, Massachusetts, March 4, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are p |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 4, 2024 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2024 |
ACRV / Acrivon Therapeutics, Inc. / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm243573d1sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 2)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares” |
|
| February 14, 2024 |
SC 13G/A 1 p24-0648sc13ga.htm ACRIVON THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this State |
|
| February 14, 2024 |
ACRV / Acrivon Therapeutics, Inc. / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to |
|
| February 14, 2024 |
EX-99.1 2 d764292dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 13, 2024 |
ACRV / Acrivon Therapeutics, Inc. / Sands Capital Ventures, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240. |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 7, 2024 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 8, 2024 |
Exhibit 99.1 Acrivon Therapeutics Appoints Seasoned Industry Executive Ivana Magovčević-Liebisch, Ph.D., J.D., to Board of Directors WATERTOWN, Massachusetts, February 8, 2024 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to |
|
| January 8, 2024 |
ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) OVERCOMING LIMITATIONS OF GENETICS-BASED PRECISION MEDICINE CORPORATE PRESENTATION JANUARY 2024 Exhibit 99. |
|
| January 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| December 12, 2023 |
December 12, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549-3720 Attention: Tamika N. Sheppard Re: Acrivon Therapeutics, Inc. Registration Statement on Form S-3 File No. 333-275854 Acceleration Request Requested Date: December 15, 2023 Requested Time: 4:30 P.M., Eastern Time Ladies and Gentlemen: Pursuant to Rule 461 |
|
| December 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 4, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commis |
|
| December 1, 2023 |
Exhibit 4.3 ACRIVON THERAPEUTICS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 3 Section 1.3. Incorporation by Reference of Trust Indenture Act 4 Section 1.4. Rules of Construction 4 ARTICLE II. THE SECURITIES 4 Section 2.1. Issuable in Series 4 Section 2.2. Estab |
|
| December 1, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Acrivon Therapeutics, Inc. |
|
| December 1, 2023 |
As filed with the Securities and Exchange Commission on December 1, 2023 Table of Contents As filed with the Securities and Exchange Commission on December 1, 2023 Registration No. |
|
| December 1, 2023 |
Exhibit 1.2 ACRIVON THERAPEUTICS, INC. $100,000,000 SHARES OF COMMON STOCK, PAR VALUE $0.001 PER SHARE SALES AGREEMENT December 1, 2023 Cowen and Company, LLC 599 Lexington Avenue New York, NY 10022 Ladies and Gentlemen: Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“TD Cowen”), as follows: 1. Issuance and |
|
| November 9, 2023 |
Exhibit 99.2 Acrivon T h e r a p e u t i c s ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3) OV E R C O M I N G L I M I TAT I O N S O F G E N E T I C S—B A S E D P R E C I S I O N M E D I C I N E C O R P O R AT E P R E S E N TAT I O N N OV E M B E R 2 0 2 3 F O R W A R D—L O O K I N G S T A T E M E N T S Certain meaning of information the Privatecontained Securities in Litigation this presentation R |
|
| November 9, 2023 |
Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights Exhibit 99.1 Acrivon Therapeutics Reports Third Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, November 9, 2023 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 9, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commis |
|
| November 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| September 5, 2023 |
EX-99.2 Exhibit 99.2 Acriv Acrivon on Thera Therapeutics peutics ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS CORPORATE PRESENTATION SEPTEMBER 2023 FORWARD -LOOKING STATEMENTS Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 regard |
|
| September 5, 2023 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 5, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commi |
|
| September 5, 2023 |
EX-99.1 Exhibit 99.1 Acrivon Therapeutics Announces ACR-2316, a Novel Dual WEE1 and PKMYT1 Inhibitor Development Candidate, Designed Using Acrivon’s AP3 Platform to Achieve Potent Single Agent Activity, as Demonstrated in Preclinical Studies Acrivon’s Predictive Precision Proteomics (AP3) platform is a proprietary, broadly applicable, next-generation precision oncology platform at the forefront of |
|
| August 11, 2023 |
As filed with the Securities and Exchange Commission on August 11, 2023 S-8 As filed with the Securities and Exchange Commission on August 11, 2023 Registration No. |
|
| August 11, 2023 |
Calculation of Filing Fee Table EXHIBIT 107 Calculation of Filing Fee Table FORM S-8 (Form Type) Acrivon Therapeutics, Inc. |
|
| August 11, 2023 |
Exhibit 10.2 SECOND AMENDMENT TO ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT This Second Amendment to Oncosignature Companion Diagnostic Agreement (the “Second Amendment”) is made and entered into as of June 19, 2023 (the “Second Amendment Effective Date”) by and between: Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at 480 Arsenal Way, Suite 100, Waterto |
|
| August 11, 2023 |
Exhibit 4.3 ACRIVON THERAPEUTICS, INC. 2023 INDUCEMENT PLAN 1. PURPOSE OF PLAN The purpose of this Acrivon Therapeutics, Inc. 2023 Inducement Plan (this “Plan”) of Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company by providing a material inducement for the best available individuals to join the Company and its Subsidiaries as employees b |
|
| August 11, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| August 11, 2023 |
Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights EX-99.1 Exhibit 99.1 Acrivon Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, August 11, 2023 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each s |
|
| August 11, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 22, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| June 5, 2023 |
Contract of Employment, dated as of May 30, 2023, by and between Acrivon AB and Kristina M. Masson.* EX-10.2 Exhibit 10.2 EMPLOYMENT CONTRACT On this day this the following contract of employment (“the Agreement”) has been entered into between (1) Acrivon AB, org. nr. 559152-0944, and (2) Kristina Masson, 19800313-0161, Nordanväg 8, 222 28 LUND, Sweden. Acrivon AB hereinafter referred to as (”Employer”). Kristina Masson, hereinafter referred to as (“Employee”). The Employer and the Employee are c |
|
| June 5, 2023 |
EX-10.1 Exhibit 10.1 AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (this “Agreement”), is entered into this 30th day of May, 2023, and is by and between Acrivon Therapeutics Inc., a Delaware corporation (“Company”), and Kristina M. Masson (“Executive”), and made effective as of June 1, 2023 (the “A&R Effective Date”). WHEREAS, the Comp |
|
| June 5, 2023 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 30, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 30, 2023 |
DEFR14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2) |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 9, 2023 |
Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights EX-99.1 2 d421791dex991.htm EX-99.1 Exhibit 99.1 Acrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights WATERTOWN, Massachusetts, May 9, 2023 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to |
|
| May 1, 2023 |
DEFA14A 1 c-acrivonproxy2023notice.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission On |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 1, 2023 |
EX-99.1 Exhibit 99.1 A Acr criv ivon on T T h h e e r r a a p p e e u u t t ii c c s s ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS INVESTOR EVENT MAY 01, 2023 F O R W A R D - L O O K I N G S T A T E M E N T S Certain information contained in this presentation includes forward-looking statements within the meaning of the Private Securities Li |
|
| May 1, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 1, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commission |
|
| May 1, 2023 |
DEF 14A 1 acrivonproxy2023.htm DEF 14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as p |
|
| April 25, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| April 25, 2023 |
EX-99.1 Exhibit 99.1 Acriv Acrivon on Thera Therapeutics peutics ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS CORPORATE PRESENTATION APRIL 2023 ACRIVON THERAPEUTICS: DRUG -TAILORED PATIENT SELECTION AIMING TO OVERCOME THE KEY ATTRITION FACTOR PREVENTING CLINICALLY ACTIVE DRUGS FROM REACHING MARKET ® AP3 Platform OncoSignature ACR-368 (Prexase |
|
| March 30, 2023 |
ACRV / Acrivon Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1) ACRIVON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter K |
|
| March 29, 2023 |
Calculation of Filing Fee Table Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 Acrivon Therapeutics, Inc. |
|
| March 29, 2023 |
Power of Attorney (included on the signature page of this Form S-8). S-8 As filed with the Securities and Exchange Commission on March 29, 2023 Registration No. |
|
| March 28, 2023 |
Exhibit 10.13 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is made and entered into this 5th day of October, 2020 (the “Effective Date”), and is by and between Acrivon Therapeutics Inc., a Delaware corporation (“Company”), and Kristina M. Masson (“Executive”). WHEREAS, Company wishes to employ Executive to continue as its Senior Vice President of Global Ope |
|
| March 28, 2023 |
Description of registrant’s securities. Exhibit 4.1 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 Acrivon Therapeutics, Inc. has one class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”): its common stock, $0.001 par value per share (the “common stock”). For the purpose of this exhibit, unless the context o |
|
| March 28, 2023 |
EX-99.1 Exhibit 99.1 Acrivon Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights WATERTOWN, Massachusetts, March 28, 2023 – Acrivon Therapeutics, Inc. (“Acrivon” or “Acrivon Therapeutics”) (Nasdaq: ACRV), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensit |
|
| March 28, 2023 |
Exhibit 21.1 ACRIVON THERAPEUTICS, INC. SUBSIDIARIES 1. Acrivon AB, a joint stock company incorporated under the laws of Sweden 2. Acrivon Securities Corporation, a Massachusetts corporation |
|
| March 28, 2023 |
Exhibit 10.14 First Amendment to ONCOSIGNATURE COMPANION DIAGNOSTIC Agreement This First Amendment to Oncosignature Companion Diagnostic Agreement (the “First Amendment”) is made and entered into as of December 21, 2022 (the “First Amendment Effective Date”) by and between: Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at 480 Arsenal Way, Suite 100, Watert |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-41551 Acrivon Therape |
|
| March 28, 2023 |
Exhibit 10.12 Acrivon Therapeutics, Inc. 480 Arsenal Way Suite 100 Watertown, MA 02472 March 30, 2022 Dear Rasmus Jorgensen, It is with great pleasure that I offer you employment with Acrivon Therapeutics, Inc. (“Acrivon” or the “Company”). Your position will be Chief Financial Officer, reporting to Peter Blume- Jensen, and your effective date of employment as a regular, full-time employee will be |
|
| March 28, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 13, 2023 |
EX-99.1 Exhibit 99.1 Acriv Acrivon on Thera Therapeutics peutics ACRIVON PREDICTIVE PRECISION PROTEOMICS (AP3): DRUG-TAILORED PATIENT SELECTION FOR CLINIC AL SUCCESS MARCH, 2023 ACRIVON THERAPEUTICS: DRUG -TAILORED PATIENT SELECTION AIMING TO OVERCOME THE KEY ATTRITION FACTOR PREVENTING CLINICALLY ACTIVE DRUGS FROM REACHING MARKET ® AP3 Platform OncoSignature ACR-368 (Prexasertib) Pipeline - Acriv |
|
| March 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| March 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2023 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| February 14, 2023 |
SC 13G 1 p23-0196sc13g.htm ACRIVON THERAPEUTICS, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) |
|
| February 14, 2023 |
EX-99.1 2 d463364dex991.htm EX-99.1 EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. This agreement is intended to satisfy the requirements of Rule 13d-1(k)(1)(iii) under the Securities Exchange Act of 1934. Date: February 14, 2 |
|
| February 14, 2023 |
ACRV / Acrivon Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 tm233236-31sc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. 1)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares |
|
| February 14, 2023 |
ACRV / Acrivon Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G/A Passive Investment SC 13G/A 1 d463364dsc13ga.htm SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement |
|
| February 14, 2023 |
ACRV / Acrivon Therapeutics Inc / Sands Capital Ventures, LLC Passive Investment SC 13G/A 1 13ga1acrivon.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO Section 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO Section 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. 1) Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par |
|
| December 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q de[ UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41551 Acrivon Therapeutics, Inc. |
|
| November 28, 2022 |
ACRV / Acrivon Therapeutics Inc / Chione Ltd - SCHEDULE 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No.)* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 004890109 (CUSIP Number) November 17, 2022 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which thi |
|
| November 28, 2022 |
Joint Filing Agreement, dated November 25, 2022, among the Reporting Persons Exhibit 99.1 JOINT FILING AGREEMENT Pursuant to and in accordance with the Securities Exchange Act of 1934, as amended (the ?Exchange Act?), and the rules and regulations thereunder, each party hereto hereby agrees to the joint filing, on behalf of each of them, of any filing required by such party under Section 13 of the Exchange Act or any rule or regulation thereunder (including any amendment, |
|
| November 28, 2022 |
ACRV / Acrivon Therapeutics Inc / RA CAPITAL MANAGEMENT, L.P. - SC 13D Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) ACRIVON THERAPEUTICS, INC. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) RA Capital Management, L.P. 200 Berkeley Street, 18th Floor Boston, MA 02116 Telephone: 617.778.2500 Attn: Peter Ko |
|
| November 25, 2022 |
SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 Under the Securities Exchange Act of 1934 (Amendment No. )* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, $0.001 par value per share (Title o |
|
| November 21, 2022 |
ACRV / Acrivon Therapeutics Inc / CITADEL ADVISORS LLC - SC 13G Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G* (Rule 13d-102) INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO § 240.13d-1(b), (c), AND (d) AND AMENDMENTS THERETO FILED PURSUANT TO § 240.13d-2 (Amendment No. )* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (the “Shares”) (Title of Class of Securities) 004890109 |
|
| November 21, 2022 |
EXHIBIT 99.1 JOINT FILING AGREEMENT The undersigned hereby agree that the Statement on Schedule 13G filed herewith (and any amendments thereto), relating to the Shares of Acrivon Therapeutics, Inc., a Delaware corporation, is being filed jointly with the Securities and Exchange Commission pursuant to Rule 13d-1(c) under the Securities Exchange Act of 1934, as amended, on behalf of each of the unde |
|
| November 18, 2022 |
ACRV / Acrivon Therapeutics Inc / PERCEPTIVE ADVISORS LLC - SC 13G Passive Investment SC 13G 1 d118896dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Acrivon Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.001 per share (Title of Class of Securities) 004890109 (CUSIP Number) November 17, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| November 18, 2022 |
EXHIBIT 1 AGREEMENT The persons below hereby agree that the Schedule 13G to which this agreement is attached as an exhibit, as well as all future amendments to such Schedule 13G, shall be filed on behalf of each of them. |
|
| November 17, 2022 |
Exhibit 99.1 SHARE PURCHASE AGREEMENT This SHARE PURCHASE AGREEMENT (this ?Agreement?) is entered into as of November 14, 2022 (the ?Effective Date?), by and between Chione Limited (the ?Investor?), and Acrivon Therapeutics, Inc., a Delaware corporation (the ?Company?). WHEREAS, the Company is proposing to issue and sell to the Investor (the ?Offering?) $5,000,000 of the Company?s common stock, $0 |
|
| November 17, 2022 |
EX-FILING FEES 4 d402028dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Registration Statement on Form S-8 Acrivon Therapeutics, Inc. Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Commo |
|
| November 17, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 14, 2022 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 001-41551 82-5125532 (State or Other Jurisdiction of Incorporation) (Commi |
|
| November 17, 2022 |
Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACRIVON THERAPEUTICS, INC. Acrivon Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?DGCL?), hereby certifies that: ONE: The name of this corporation is Acrivon Therapeutics, Inc. and the date of filing of the original Certificate of Incorpor |
|
| November 17, 2022 |
Exhibit 3.2 AMENDED AND RESTATED BYLAWS OF ACRIVON THERAPEUTICS, INC. (A DELAWARE CORPORATION) SECTION 1. OFFICES Section 1.1 Registered Office. The registered office of Acrivon Therapeutics, Inc. (the ?Corporation?) in the State of Delaware and the name of the Corporation?s registered agent at such address shall be as set forth in the certificate of incorporation of the Corporation (as the same m |
|
| November 17, 2022 |
As filed with the Securities and Exchange Commission on November 17, 2022 As filed with the Securities and Exchange Commission on November 17, 2022 Registration No. |
|
| November 16, 2022 |
424B4 Table of Contents Filed Pursuant to Rule 424(b)(4) Registration Nos. 333-267911 and 333-268365 7,550,000 Shares Common Stock We are offering 7,550,000 shares of our common stock. This is our initial public offering, and no public market currently exists for shares of our common stock. The initial public offering price for our common stock is $12.50 per share. Our common stock has been approv |
|
| November 14, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Acrivon Therapeutics, Inc. |
|
| November 14, 2022 |
Issuer Free Writing Prospectus dated November 14, 2022 Filed pursuant to Rule 433 Relating to the Preliminary Prospectus dated November 8, 2022 Registration File No. |
|
| November 14, 2022 |
As filed with the Securities and Exchange Commission on November 14, 2022. As filed with the Securities and Exchange Commission on November 14, 2022. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 2834 82-5125532 (State or other jurisdiction of incorporation or organizati |
|
| November 8, 2022 |
As filed with the Securities and Exchange Commission on November 8, 2022. S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 8, 2022. |
|
| November 7, 2022 |
8-A12B 1 d383050d8a12b.htm 8-A12B UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Acrivon Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 82-5125532 (State of Incorporation or Organization) (I.R.S. Employer Ide |
|
| November 7, 2022 |
CORRESP 1 filename1.htm November 7, 2022 VIA EDGAR U.S. Securities and Exchange Commission Office of Life Sciences Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford Jason Drory Li Xiao Lynn Dicker Re: Acrivon Therapeutics, Inc. Registration Statement on Form S-1 Registration No. 333-267911 Acceleration Request Requested Date: November 9, 2022 Requested |
|
| November 7, 2022 |
Acrivon Therapeutics, Inc. 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 Acrivon Therapeutics, Inc. 480 Arsenal Way, Suite 100 Watertown, Massachusetts 02472 November 7, 2022 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549 Attn: Daniel Crawford, Jason Drory, Li Xiao, Lynn Dicker Re: Acrivon Therapeutics, Inc. Registration Statement on Form S-1, as amended (File No. 333-2 |
|
| November 3, 2022 |
Certificate of Amendment to Second Amended and Restated Certificate of Incorporation EX-3.5 5 d383050dex35.htm EX-3.5 Exhibit 3.5 CERTIFICATE OF AMENDMENT TO SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACRIVON THERAPEUTICS, INC. ACRIVON THERAPEUTICS, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify: FIRST: The name of the corporation is Acrivon Therapeutics, Inc. |
|
| November 3, 2022 |
As filed with the Securities and Exchange Commission on November 3, 2022. S-1/A Table of Contents As filed with the Securities and Exchange Commission on November 3, 2022. |
|
| November 3, 2022 |
Exhibit 3.3 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACRIVON THERAPEUTICS, INC. Acrivon Therapeutics, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of the Delaware (the ?DGCL?), hereby certifies that: ONE: The name of this corporation is Acrivon Therapeutics, Inc. and the date of filing of the original Certificate of Incorpor |
|
| November 3, 2022 |
Exhibit 10.3 ACRIVON THERAPEUTICS, INC. 2022 EMPLOYEE STOCK PURCHASE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 28, 2022 APPROVED BY THE STOCKHOLDERS: NOVEMBER 1, 2022 1. GENERAL; PURPOSE. (a) The Plan provides a means by which Eligible Employees of the Company and certain Designated Companies may be given an opportunity to purchase shares of Common Stock. The Plan permits the Company to gran |
|
| November 3, 2022 |
Exhibit 10.11 ACRIVON THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION POLICY Each member of the Board of Directors (the ?Board?) of Acrivon Therapeutics, Inc. (the ?Company?) who is a non-employee director of the Company (each, a ?Non-Employee Director?) will receive the compensation described in this Non-Employee Director Compensation Policy (this ?Director Compensation Policy?) for his or |
|
| November 3, 2022 |
Form of Underwriting Agreement EX-1.1 2 d383050dex11.htm EX-1.1 Exhibit 1.1 [•] Shares ACRIVON THERAPEUTICS, INC. COMMON STOCK, PAR VALUE $0.001 PER SHARE UNDERWRITING AGREEMENT [•], 2022 Morgan Stanley & Co. LLC Jefferies LLC Cowen and Company, LLC Piper Sandler & Co. c/o Morgan Stanley & Co. LLC 1585 Broadway New York, New York 10036 c/o Jefferies LLC 520 Madison Avenue New York, New York 10022 c/o Cowen and Company, LLC 599 |
|
| November 3, 2022 |
Exhibit 10.2 ACRIVON THERAPEUTICS, INC. 2022 EQUITY INCENTIVE PLAN ADOPTED BY THE BOARD OF DIRECTORS: OCTOBER 28, 2022 APPROVED BY THE STOCKHOLDERS: NOVEMBER 1, 2022 1. GENERAL. (a) Successor to and Continuation of Prior Plan. The Plan is the successor to and continuation of the Prior Plan. As of the Effective Date, (i) no additional awards may be granted under the Prior Plan; (ii) the Prior Plan? |
|
| November 3, 2022 |
EX-FILING FEES 11 d383050dexfilingfees.htm EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Acrivon Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offerin |
|
| November 3, 2022 |
Exhibit 3.4 AMENDED AND RESTATED BYLAWS OF ACRIVON THERAPEUTICS, INC. (A DELAWARE CORPORATION) SECTION 1. OFFICES Section 1.1 Registered Office. The registered office of Acrivon Therapeutics, Inc. (the ?Corporation?) in the State of Delaware and the name of the Corporation?s registered agent at such address shall be as set forth in the certificate of incorporation of the Corporation (as the same m |
|
| October 17, 2022 |
Bylaws of the Registrant (currently in effect) Exhibit 3.2 BY-LAWS OF ACRIVON THERAPEUTICS, INC. TABLE OF CONTENTS Page SECTION 1. NAME 1 SECTION 2. OFFICES 1 2.1 Registered Office 1 2.2 Other Offices 1 SECTION 3. STOCKHOLDERS 1 3.1 Location of Meetings 1 3.2 Annual Meeting 1 3.3 Special Meetings 1 3.4 Notice of Meetings 2 3.5 Stockholder List 2 3.6 Quorum of Stockholders 2 3.7 Adjournment 2 3.8 Voting; Proxies 3 3.9 Inspectors 3 3.10 Action b |
|
| October 17, 2022 |
Exhibit 4.1 EXECUTION VERSION AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of November 9, 2021, by and among ACRIVON THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. RECITALS WHERE |
|
| October 17, 2022 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Acrivon Therapeutics, Inc. |
|
| October 17, 2022 |
Exhibit 10.8 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the ?Agreement?), is made and entered into this 5th day of October, 2020 (the ?Effective Date?), and is by and between Acrivon Therapeutics, Inc., a Delaware corporation (?Company?), and Peter Blume-Jensen (?Executive?). WHEREAS, Company wishes to employ Executive to continue to serve as its President, Chief Executive |
|
| October 17, 2022 |
Exhibit 21.1 ACRIVON THERAPEUTICS, INC. SUBSIDIARIES 1. Acrivon AB, a joint stock company incorporated under the laws of Sweden 2. Acrivon Securities Corporation, a Massachusetts corporation |
|
| October 17, 2022 |
Form of Indemnification Agreement with Executive Officers and Directors Exhibit 10.4 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the ?Agreement?) is made and entered into as of [?] between Acrivon Therapeutics, Inc., a Delaware corporation (the ?Company?), and [?] (?Indemnitee?). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as officers or directors or in other capacities unless they are provided with |
|
| October 17, 2022 |
Patent License Agreement, by and between the Registrant and Peter Blume-Jensen, dated April 12, 2018 Exhibit 10.7 PATENT LICENSE AGREEMENT THIS AGREEMENT is made this 12th day of April, 2018 (?Effective Date?), by and between Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at [***] (?Licensee?) and Peter Blume-Jensen, an individual residing at [***] (?Licensor?) with reference to the following facts: WHEREAS, Licensor has developed and owns certain patents |
|
| October 17, 2022 |
License Agreement, by and between the Registrant and Eli Lilly and Company, dated January 27, 2021 Exhibit 10.5 Certain information has been excluded from this agreement (indicated by ?[***]?) because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. Execution Copy LICENSE AGREEMENT This LICENSE AGREEMENT (this ?Agreement?), effective as of January 27, 2021 (the ?Effective Date?), is entered into by and between ACRIVON THERAPEUTICS, |
|
| October 17, 2022 |
Exhibit 10.10 Acrivon Therapeutics, Inc. Lab Central 700 North Main St. Cambridge, MA 02139 [***] October 5, 2020 Eric Devroe [***] [***] Dear Eric Devroe, It is with great pleasure that I offer you employment with Acrivon Therapeutics, Inc. (?Acrivon? or the ?Company?). Your title will be Senior Vice President (SVP) of Business Operations, a remote position reporting to Peter Blume-Jensen, Presid |
|
| October 17, 2022 |
Power of Attorney (included on signature page) S-1 Table of Contents As filed with the Securities and Exchange Commission on October 17, 2022. |
|
| October 17, 2022 |
Exhibit 10.9 Acrivon Therapeutics, Inc. Lab Central 700 North Main St. Cambridge, MA 02139 [***] February 26, 2021 Dear Erick Gamelin, Position It is with great pleasure that I offer you employment with Acrivon Therapeutics, Inc. (?Acrivon? or the ?Company?). Your title will be Chief Medical Officer, a remote position reporting to Peter Blume-Jensen, President and CEO. Your effective date of emplo |
|
| October 17, 2022 |
2019 Stock Incentive Plan and Forms of Stock Option Agreement and Notice of Exercise Exhibit 10.1 2019 STOCK INCENTIVE PLAN OF ACRIVON THERAPEUTICS, INC. 1. Purpose The purpose of this 2019 Stock Incentive Plan (the ?Plan?) of Acrivon Therapeutics, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| October 17, 2022 |
Exhibit 10.6 Certain information has been excluded from this agreement (indicated by ?[***]?) because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. EXECUTION COPY Confidential ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT This ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (this ?Agreement?), effective as of June 17, 2022 (the ?Effect |
|
| October 17, 2022 |
CORRESP 1 filename1.htm Ryan Sansom +1 617 937 2335 [email protected] October 17, 2022 Daniel Crawford Jason Drory Li Xiao Lynn Dicker Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Acrivon Therapeutics, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted September 22, 2022 CIK No |
|
| October 17, 2022 |
Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACRIVON THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Acrivon Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the ?General Corporation Law?), DOES HEREBY CERTIF |
|
| September 22, 2022 |
2019 STOCK INCENTIVE PLAN OF ACRIVON THERAPEUTICS, INC. Exhibit 10.1 2019 STOCK INCENTIVE PLAN OF ACRIVON THERAPEUTICS, INC. 1. Purpose The purpose of this 2019 Stock Incentive Plan (the ?Plan?) of Acrivon Therapeutics, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make important contributions to the C |
|
| September 22, 2022 |
BY-LAWS ACRIVON THERAPEUTICS, INC. EX-3.2 3 filename3.htm Exhibit 3.2 BY-LAWS OF ACRIVON THERAPEUTICS, INC. TABLE OF CONTENTS Page SECTION 1. NAME 1 SECTION 2. OFFICES 1 2.1 Registered Office 1 2.2 Other Offices 1 SECTION 3. STOCKHOLDERS 1 3.1 Location of Meetings 1 3.2 Annual Meeting 1 3.3 Special Meetings 1 3.4 Notice of Meetings 2 3.5 Stockholder List 2 3.6 Quorum of Stockholders 2 3.7 Adjournment 2 3.8 Voting; Proxies 3 3.9 Ins |
|
| September 22, 2022 |
EXECUTIVE EMPLOYMENT AGREEMENT EX-10.7 8 filename8.htm Exhibit 10.7 EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”), is made and entered into this 5th day of October, 2020 (the “Effective Date”), and is by and between Acrivon Therapeutics, Inc., a Delaware corporation (“Company”), and Peter Blume-Jensen (“Executive”). WHEREAS, Company wishes to employ Executive to continue to serve as its Pr |
|
| September 22, 2022 |
EX-3.1 2 filename2.htm Exhibit 3.1 SECOND AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF ACRIVON THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Acrivon Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation La |
|
| September 22, 2022 |
EX-10.6 7 filename7.htm Exhibit 10.6 PATENT LICENSE AGREEMENT THIS AGREEMENT is made this 12th day of April, 2018 (“Effective Date”), by and between Acrivon Therapeutics, Inc., a Delaware corporation with its principal place of business at [***] (“Licensee”) and Peter Blume-Jensen, an individual residing at [***] (“Licensor”) with reference to the following facts: WHEREAS, Licensor has developed a |
|
| September 22, 2022 |
AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT Exhibit 4.1 EXECUTION VERSION AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS? RIGHTS AGREEMENT (this ?Agreement?), is made as of November 9, 2021, by and among ACRIVON THERAPEUTICS, INC., a Delaware corporation (the ?Company?), and each of the investors listed on Schedule A hereto, each of which is referred to in this Agreement as an ?Investor?. RECITALS WHERE |
|
| September 22, 2022 |
EX-10.3 6 filename6.htm Exhibit 10.3 INDEMNIFICATION AGREEMENT THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of [•] between Acrivon Therapeutics, Inc., a Delaware corporation (the “Company”), and [•] (“Indemnitee”). WITNESSETH THAT: WHEREAS, highly competent persons have become more reluctant to serve corporations as directors or in other capacities unless they are p |
|
| September 22, 2022 |
Table of Contents As confidentially submitted to the Securities and Exchange Commission on September 22, 2022. |
|
| September 22, 2022 |
Ryan Sansom +1 617 937 2335 [email protected] September 22, 2022 Daniel Crawford Jason Drory Li Xiao Lynn Dicker Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Acrivon Therapeutics, Inc. Draft Registration Statement on Form S-1 Submitted August 12, 2022 CIK No. 0001781174 Ladies and Gentlemen: On behalf |
|
| September 22, 2022 |
Exhibit 10.8 Acrivon Therapeutics, Inc. Lab Central 700 North Main St. Cambridge, MA 02139 617-888-0830 February 26, 2021 Dear Erick Gamelin, Position It is with great pleasure that I offer you employment with Acrivon Therapeutics, Inc. (?Acrivon? or the ?Company?). Your title will be Chief Medical Officer, a remote position reporting to Peter Blume-Jensen, President and CEO. Your effective date o |
|
| September 22, 2022 |
EX-21.1 11 filename11.htm Exhibit 21.1 ACRIVON THERAPEUTICS, INC. SUBSIDIARIES 1. Acrivon AB, a joint stock company incorporated under the laws of Sweden 2. Acrivon Securities Corporation, a Massachusetts corporation |
|
| September 22, 2022 |
EX-10.9 10 filename10.htm Exhibit 10.9 Acrivon Therapeutics, Inc. Lab Central 700 North Main St. Cambridge, MA 02139 617-888-0830 October 5, 2020 Eric Devroe [***] [***] Dear Eric Devroe, It is with great pleasure that I offer you employment with Acrivon Therapeutics, Inc. (“Acrivon” or the “Company”). Your title will be Senior Vice President (SVP) of Business Operations, a remote position reporti |
|
| August 12, 2022 |
DRS 1 filename1.htm As confidentially submitted to the Securities and Exchange Commission on August 12, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER |
|
| August 12, 2022 |
ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT EX-10.5 3 filename3.htm Exhibit 10.5 Certain information has been excluded from this agreement (indicated by “[***]”) because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. EXECUTION COPY Confidential ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT This ONCOSIGNATURE COMPANION DIAGNOSTIC AGREEMENT (this “Agreement”), effective as of Ju |
|
| August 12, 2022 |
Exhibit 10.4 Certain information has been excluded from this agreement (indicated by ?[***]?) because such information (i) is not material and (ii) is the type that the registrant treats as private or confidential. Execution Copy LICENSE AGREEMENT This LICENSE AGREEMENT (this ?Agreement?), effective as of January 27, 2021 (the ?Effective Date?), is entered into by and between ACRIVON THERAPEUTICS, |
